BPC-157 infusion pilot
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
Lee E, Burgess K. · Alternative therapies in health and medicine
Study record
- Population
Two adults, aged 58 and 68, previously exposed to intravenous BPC-157.
Read source · Full-text reportParticipants, p.20; Patients, p.21- Formulation
Compounded solution, 2 mg/mL; pharmacy unnamed.
Read source · Full-text reportProcedure, p.21- Route
Intravenous infusion.
Read source · Full-text reportProcedure, p.21- Dose & frequency
10 mg on day 1, then 20 mg on day 2; each in 250 mL saline over one hour. Reported experiment, not a validated regimen.
Read source · Full-text reportProcedure, p.21- Study design
Single-clinic, uncontrolled two-person pilot.
Read source · Full-text reportMethods, p.21- Duration
Two treatment days; assessments through day 3.
Read source · Full-text reportProcedure, p.21- Reported findings
Authors reported no clinically important biomarker changes. No efficacy endpoint was tested.
Read source · Full-text reportResults and Discussion, p.22- Adverse events
No symptoms reported through 24 hours after the second infusion; rare or delayed harms cannot be assessed.
Read source · Full-text reportResults, p.22- Monitoring
Blood tests, vital signs and symptom questions before/after infusions and on day 3.
Read source · Full-text reportProcedure, p.21
What it supports
Describes short-term observations only.
What it does not establish
No comparator, two previously exposed volunteers, brief follow-up. Cannot establish general safety, efficacy or a cycling schedule.
Funding
Unfunded; participants paid treatment/laboratory costs (Patients p.21; Limitations p.23).
Literature search cutoff: 2026-09-08 · Not independently clinically reviewed
Browse study library